ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
ASP Isotopes Inc. (ASPI) reports that officer Robert Ainscow has filed a notice under Rule 144 to sell common stock through Independent Trading Group. The notice covers planned sales of 25,000 and 8,438 shares on NASDAQ, with an aggregate market value based on a $3.78 closing price on September 1, 2026. The shares relate to a previously granted 300,000-share restricted stock award under an issuer equity incentive plan, and the filing states that part of the sale is to satisfy income tax liabilities from quarterly vesting.
ASP Isotopes Inc. (ASPI) has a notice of proposed sale under Rule 144 for common stock held for the account of Donald George Ainscow. J.P. Morgan Securities LLC, acting as agent and attorney-in-fact, plans to sell 50,000 shares of ASP Isotopes common stock. The proposed sale has an aggregate market value of $194,390.65, with ASP Isotopes reporting 125,903,447 shares outstanding as of September 2, 2026, which is a baseline figure, not the amount being sold. Ainscow previously acquired 400,000 shares on August 1, 2025 as a restricted stock award and sold 100,000 shares on June 30, 2026 for $614,000.
ASP Isotopes Inc. (ASPI) reported that its wholly owned subsidiary Renergen Limited entered into a Second Amendment and Restatement Agreement with The Standard Bank of South Africa, replacing a prior secured term loan facility. The amended facility provides a secured ZAR230,532,658.90 term loan (approximately USD14.2 million) that now includes previously accrued, unpaid and capitalized interest from the earlier agreement.
The loan bears interest at the Compounded Reference Rate plus 1.46%, for an effective rate of 8.31%, and matures on August 14, 2027. Renergen must maintain a Collateral Account with the lender with a balance at least equal to the full commitment, over which the lender has exclusive control and from which it may debit interest on each payment date. The agreement imposes negative covenants and broad cross-default provisions tied to financial indebtedness of Renergen, Tetra4, NTIGT and ASP Isotopes. In a related Put Option Agreement, ASP Isotopes granted the lender an irrevocable right, upon a continuing Event of Default, to require ASP Isotopes or its nominee to purchase 1,546,268 pledged ASP Isotopes shares at 100% of the five-day JSE volume-weighted average price, with proceeds applied to reduce or discharge the loan.
ASP Isotopes Inc. (ASPI) reports that Tetra4, a subsidiary of Renergen and developer of the Virginia Gas Project in South Africa, has entered the commissioning phase of ASP’s liquid helium plant. First commercial helium shipments to customers are expected during September, with production ramping to nameplate capacity in the second half of 2026.
Phase 1 of the project is expected to produce approximately 2,500 GJ/day of LNG and 70 Mcf/day of liquid helium, supporting projected annualized revenues of over $27 million once fully ramped, based on stated price assumptions. ASP currently has take-or-pay contracts covering about 75% of Phase 1 LNG and 15% of Phase 1 helium volumes.
ASP plans a much larger Phase 2, targeted to be roughly 13 times the size of Phase 1, with construction expected to start in the second half of 2026 and take about 44 months. The company intends to pursue up to $750 million in senior debt funding from the U.S. International Development Finance Corporation and Standard Bank of South Africa, subject to negotiation and definitive agreements. The disclosure also describes a planned reverse merger involving Noble Africa and ENDRA Life Sciences and related SEC filings.
ASP Isotopes Inc. reported that its wholly owned subsidiary, Quantum Leap Energy LLC, is evaluating metal conversion opportunities in Namibia. The subsidiary has begun a public environmental and social impact assessment and consultation process for a proposed pilot-scale hydrofluorination and fluorination facility in the Walvis Bay area. The potential facility would be used to develop, test, and demonstrate hydrofluorination and fluorination processes for metals. The evaluation is at an early stage, with no final investment decision made, and any future development would be subject to technical, commercial, environmental, and regulatory review and approvals.
Quantum Leap Energy is described as a development-stage nuclear fuels company focused on uranium conversion, enrichment technologies and isotopic separation for advanced reactors and fusion systems, while ASP Isotopes develops isotope enrichment technologies for nuclear medicine, semiconductors, and nuclear energy.
ASP Isotopes Inc. reported strong top-line growth but continued significant losses for the quarter and six months ended June 30, 2026. Total revenue rose to $9.3 million for the first half of 2026 from $2.3 million a year earlier, driven by specialist isotopes, new U.S. radiopharmacy operations and initial helium and LNG sales from the Renergen acquisition, plus collaboration revenue from TerraPower.
Despite higher revenue and gross profit of $3.1 million, the company posted a loss from continuing operations of $60.7 million for the first half and a net loss attributable to shareholders of $40.5 million, reflecting heavy R&D and selling, general and administrative expenses as it builds out isotope, nuclear fuel and gas projects. Operating cash outflow from continuing operations was $40.0 million, and investing outflow was $57.2 million, including major spending on property, natural gas assets and equity investments.
Liquidity remains substantial, with $219.6 million in cash and cash equivalents and $35.3 million in short-term U.S. Treasury investments as of June 30, 2026. Management states this balance should fund operating and capital needs for more than 12 months, though it anticipates raising additional equity, debt or partnership funding over time. The balance sheet also includes $203.4 million of convertible notes carried at fair value and $192.9 million of natural gas properties from Renergen.
ASP Isotopes describes that Tetra4 Proprietary Limited, a subsidiary of its subsidiary Renergen Limited, has signed a new five-year, take-or-pay contract to supply liquified natural gas to a South African food processor at a price per unit of greater than $16/GJ of LNG on an all-in plant-gate basis. The agreement represents about 10% of the Virginia Gas Project's Phase 1 nameplate capacity and, together with earlier contracts, supports roughly 75% of anticipated Phase 1 LNG volumes.
Phase 1 is expected to produce approximately 2,500 GJ/day of LNG and about 70 Mcf/day of liquid helium, with commercial production targeted to begin in the third quarter of 2026. ASP Isotopes states that, assuming LNG prices of $15–18 per GJ and an average helium price of $600/Mcf, Renergen should be capable of generating revenues of over $27 million on an annualized basis following completion of Phase 1, with revenue recognition expected to begin in the second half of 2026. The company also outlines a planned reverse merger of its Noble Africa subsidiary with ENDRA Life Sciences and related SEC registration and proxy processes.
ASP Isotopes Inc. disclosed that it will host investor meetings at Citi's 2026 Natural Resources Conference on August 13, 2026, in Las Vegas, Nevada. The latest investor presentation is available under the Investors tab on the company’s website.
The press release also describes ASP Isotopes’ isotope enrichment technologies and facilities in Pretoria, South Africa, and outlines proposed merger-related transactions involving ENDRA Life Sciences, Renergen and Noble Africa, for which ENDRA plans to file a Form S-4 registration statement with a proxy statement/prospectus. It emphasizes extensive forward-looking statements and risk factors, including funding needs, regulatory approvals, project execution, and the possibility that the proposed transactions may not be completed.
ASP Isotopes updates shareholders on multi‑segment growth plans ahead of releasing Q2 2026 results. Management reports that PET Labs achieved over 50% organic revenue growth in 1H 2026 and forecasts FY 2026 revenue of approximately $14 million, compared with $6 million in 2025, as demand for radiopharmaceuticals rises.
Through Renergen, the company targets helium and LNG revenues of roughly $27 million annually after Phase 1, and over $360 million at Phase 2 nameplate capacity, at stated price assumptions. Phase 2 is expected to be funded in part by about $750 million of senior debt, and ASP Isotopes plans to list Renergen’s holding vehicle Noble Africa on Nasdaq, where it expects to retain roughly 89% ownership if the transactions close.
The update highlights delays but continued technical progress in Silicon‑28 and other stable isotope facilities, a long‑term EBITDA target above $300 million by 2031 from non‑nuclear‑fuel businesses, and strategic plans for Quantum Leap Energy and Alpa Theranostics, including a potential future distribution of QLE equity to ASP Isotopes shareholders, subject to multiple conditions.
ASP Isotopes Inc., an advanced materials company developing isotope enrichment technologies, announced that Chief Commercial Officer Viktor Petkov will present at Canaccord Genuity’s 46th Annual Growth Conference on August 12, 2026, at 8:00 a.m. ET. A live audio webcast and subsequent replay will be available in the Investors section of the company’s website.
The press release also describes proposed merger and related transactions involving ENDRA Life Sciences Inc., ASP Isotopes and its subsidiaries Renergen and Noble Africa, for which ENDRA plans to file a Form S-4 registration statement containing a proxy statement and prospectus. It includes extensive "forward-looking" statements language, highlighting risks around project execution, regulatory approvals, financing, commercialization of isotope technologies, completion of the Proposed Transactions (including approval by ENDRA stockholders), and other factors discussed in ASP Isotopes’ 2025 Annual Report and subsequent SEC reports.